<DOC>
	<DOCNO>NCT00854854</DOCNO>
	<brief_summary>The purpose study determine efficacy NKCell combine FOLFOX-4 chemotherapy gastric cancer</brief_summary>
	<brief_title>Efficacy Study TKcell Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Written inform consent . Diagnosis histologically confirm adenocarcinoma gastric ECOG performance status 0 2 At least one definite measurable lesion ( ) : ≥ 1 cm spiral CT scan ≥2cm physical examination Adequate liver , renal , bone marrow function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 7.5 x 109/L ; Bilirubin le 2 mg/dL ASAT and/or ALAT &lt; 5 UNL ; serum creatinine ≤ 2 ULN Minimum life expectancy 12 week Effective contraception male female subject risk conception exists Brain metastasis and/or leptomeningeal disease ( know suspect ) Previous chemotherapy gastric cancer except adjuvant treatment progression disease document &gt; 6 month end adjuvant treatment . Previous oxaliplatinbased chemotherapy Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior randomization chemotherapy HIV antibody ( + ) , Chronic hepatitis Uncontrolled infection Concurrent previous chronic systemic immune therapy , target therapy , hormonal therapy indicate study protocol except contraception Clinically relevant coronary artery disease , history myocardial infarction , high risk uncontrolled arrhythmia Known hypersensitivity reaction component treatment . Pregnancy ( absence confirm ßhCG test ) lactation period Participation another clinical study within 30 day randomization Significant disease , investigator 's opinion , would exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>NKCell</keyword>
	<keyword>FOLFOX-4</keyword>
	<keyword>gastric cancer</keyword>
</DOC>